Edwards Lifesciences - 股票

Edwards Lifesciences 员工 2024

Edwards Lifesciences 员工

13,900

股票代码

EW

ISIN

US28176E1082

WKN

936853

在2024年,Edwards Lifesciences雇佣了13,900名员工,相较于前一年员工数量13,900,发生了0%的变化。

Edwards Lifesciences Aktienanalyse

Edwards Lifesciences在做什么?

Edwards Lifesciences Corp is a globally operating company in the field of medical technology, specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. The company was founded in California in 1958 and is now one of the leading companies in the field of modern heart valve technology. The history of Edwards Lifesciences begins with its founding by Miles "Lowell" Edwards and his longtime employee Dr. Albert Starr. They recognized the need for a less invasive and more effective alternative to heart valves than the existing surgical methods. They received their first patent in 1960 and performed their first successful heart valve operation on a sheep in the same year. The first surgeries on humans took place in 1962. Edwards Lifesciences quickly expanded in the US and internationally. The business model of Edwards Lifesciences focuses on three business areas: "Transcatheter Heart Valve Systems," "Surgical Heart Valve Therapy," and "Critical Care." Each area is focused on a specific range of products and is supported by its own team of professionals. The "Transcatheter Heart Valve Systems" area has become the most important division of Edwards Lifesciences. This novel technology enables the implantation of an artificial heart valve system through minimally invasive surgical methods, without the need for an open procedure. The system consists of a foldable heart valve made of animal tissue or artificial material, which is inserted into the damaged heart through a catheter. This method is applicable to a wide range of patients and has become an important tool in the treatment of heart diseases. The "Surgical Heart Valve Therapy" business area includes implantable mechanical and biological heart valves for open surgical procedures. Edwards Lifesciences develops innovative products to meet the needs of surgical patients and doctors. The third business area, "Critical Care," offers instruments and technologies for the critical medical care of patients in intensive care units and emergency departments. The company manufactures collagen matrix products for wound care, catheter monitoring systems, and patient monitoring devices to detect potential life-threatening complications early. Over the years, Edwards Lifesciences has introduced numerous innovative products to the market that are used in medical practice. The Edwards SAPIEN Transcatheter Heart Valve System was approved in Europe in 2011 and in the US in 2012 and has since improved the lives of tens of thousands of patients. With new technologies such as the Edwards SAPIEN 3 and SAPIEN 3 Ultra platforms, the company is constantly striving to increase the effectiveness and safety of heart disease treatment. Edwards Lifesciences is headquartered in Irvine, California, and is a multinational company with locations in North America, Europe, India, and Asia. The company currently employs approximately 14,000 people worldwide and is an important pillar of the medical community. Answer: Edwards Lifesciences Corp is a global medical technology company specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. It is a leader in modern heart valve technology. Edwards Lifesciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

员工的详细信息

Edwards Lifesciences的员工基础调查

Edwards Lifesciences的员工是其运营的关键因素,推动了创新、生产力和增长。员工队伍的规模和组成提供了公司规模、多样性以及人力资本投资的见解。分析员工数据对于理解Edwards Lifesciences的运营能力和未来潜力至关重要。

年度对比

通过年度比较Edwards Lifesciences的员工数量,有助于发现增长模式、扩张或者收缩。员工数量的增加可能表明运营正在扩大并投资于人才,而员工数量的减少可能表明效率提升、自动化或商业挑战。

对投资的影响

Edwards Lifesciences的员工数据会影响投资决策,通过揭示公司运行效率、创新能力和持续性。投资者评估员工数据,以评估公司实施策略、创新以及适应市场变化的潜力。

员工数据的解读

Edwards Lifesciences的员工数量的波动可能表明商业策略、运营需求以及市场动态的变化。投资者和分析师会研究这些趋势,以评估公司的战略定位、适应能力以及持续增长的潜力。

关于Edwards Lifesciences股票的常见问题

Edwards Lifesciences今年有多少员工?

Edwards Lifesciences今年有13,900 undefined名员工。

Edwards Lifesciences去年相比有多少员工?

与去年相比,Edwards Lifesciences的员工数量增加了0%。

员工数量对Edwards Lifesciences公司产生了什么影响?

员工数量直接影响了Edwards Lifesciences的效率和生产力。较高的员工数量可能意味着公司正在发展并拥有更多资源以实现其目标,而较低的员工数量可能意味着公司正在节约成本或在招聘新员工方面有困难。

Edwards Lifesciences的员工数量对投资者产生了什么影响?

Edwards Lifesciences的员工数量也可能影响投资者,因为它可能是公司增长和财务健康的指标。较高的员工数量可能向投资者承诺,而较少的员工数量可能会引发关注。

Edwards Lifesciences的股本增加会对公司产生什么影响?

增加Edwards Lifesciences的股本可以提高公司的财务实力,并提高其未来进行投资和履行义务的能力。

Edwards Lifesciences的股本减少会对公司产生什么影响?

降低Edwards Lifesciences的股本可能会影响其财务稳定性,并降低其履行未来投资和义务的能力。

Edwards Lifesciences的股权受到哪些因素的影响?

一些可能影响Edwards Lifesciences股本的因素包括营业收入发展、利润及损失表、派发股息和投资等。

为什么Edwards Lifesciences的股权对投资者如此重要?

Edwards Lifesciences的股本对投资者来说非常重要,因为它是公司财务稳定性的指标,并且它向投资者提供了有关该公司在义务和未来投资方面有多少财务支持的信息。

Edwards Lifesciences的员工数量如何影响公司?

Edwards Lifesciences的员工数量可以直接影响公司的增长和表现。更多的员工数量可能会带来更大的产能和生产力,而较少的员工数量可能会导致效率下降和限制。

Edwards Lifesciences在过去几年的员工人数有何变化?

在过去的几年中,Edwards Lifesciences的员工数量发生了0的变化。

Edwards Lifesciences目前有多少员工?

Edwards Lifesciences目前有13,900 undefined名员工。

为什么Edwards Lifesciences的员工人数对投资者来说很重要?

Edwards Lifesciences的投资者认为员工数量非常重要,因为它是公司增长潜力和绩效的指标。还有关于公司如何管理和招聘员工的信息。

Edwards Lifesciences可以采取哪些战略措施来改变员工数量?

为了改变员工数量,Edwards Lifesciences可以采取包括调整薪酬包,改善工作条件,进行招聘活动,和推动积极企业文化等措施。公司需要进行全面的情况审查,以确定最佳战略措施来改变其员工数量,这一点非常重要。

Edwards Lifesciences支付多少股息?

在过去的12个月中,Edwards Lifesciences支付了 的股息。这相当于大约的股息收益率。在未来的12个月内,Edwards Lifesciences预计将支付0 USD的股息。

Edwards Lifesciences的股息收益率有多高?

Edwards Lifesciences当前的股息收益率为。

Edwards Lifesciences什么时候支付股息?

Edwards Lifesciences按季度支付股息。这些股息将在月份分发。

Edwards Lifesciences的股息有多安全?

Edwards Lifesciences 在过去0年里每年都支付了股息。

Edwards Lifesciences的股息有多高?

预计未来12个月的股息将达到0 USD。这相当于0 %的股息收益率。

Edwards Lifesciences位于哪个行业?

Edwards Lifesciences 被分配到“健康”板块。

Wann musste ich die Aktien von Edwards Lifesciences kaufen, um die vorherige Dividende zu erhalten?

要获得Edwards Lifesciences在支付的0 USD的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Edwards Lifesciences最后一次支付股息是什么时候?

上一次股息发放日期为。

Edwards Lifesciences在2023年的股息是多少?

在2023年,Edwards Lifesciences 分配了0 USD作为股息。

Edwards Lifesciences 的股息是以哪种货币支付的?

Edwards Lifesciences的股息将以USD的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Edwards Lifesciences 股票在以下供应商处可进行定投计划:Trade Republic

Andere Kennzahlen von Edwards Lifesciences

我们对Edwards Lifesciences 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Edwards Lifesciences 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: